Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 7/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | TACR3 | P29371 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20883164 | 0.92 | GABRA1 (0.49) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL5201772 | 0.90 | MEN1 (0.57) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL14571605 | 0.81 | MEN1 (0.58) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL5202501 | 0.80 | MEN1 (0.58) | MEN1KMT2A | |
| SCHEMBL5203675 | 0.80 | MEN1 (0.63) | MEN1KMT2A | |
| SCHEMBL8707626 | 0.78 | TACR1 (0.61) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL1063370 | 0.77 | MEN1 (0.66) | MEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL1063365 | 0.77 | MEN1 (0.66) | MEN1KMT2A | |
| SCHEMBL20883160 | 0.77 | MEN1 (0.63) | MEN1KMT2A | |
| SCHEMBL5201937 | 0.77 | MEN1 (0.61) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2019-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383963-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, RHOXF2 | GABRA1 4059/4885GABRG2 3518/4885GABRB3 3339/4885 |
| US-10342786-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | GABRA1 4140/4885GABRG2 3526/4885GABRB3 3558/4885 |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | GABRA1 4140/4885GABRG2 3526/4885GABRB3 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.